Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Clarivate Plc(CLVT US)

$2.09+0.4325.90%Ext:$2.10+0.010.44%(Pre-Market · 12:12:58 UTC)
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Clarivate Plc(CLVT US)

$2.09+0.4325.90%Ext:$2.10+0.010.44%(Pre-Market · 12:12:58 UTC)
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees
CLVT US​
Ask AI
CLVT US​
Ask AI

Clarivate Plc — Company Profile

Clarivate Plc operates as a prominent information services and analytics firm, furnishing structured data and insights. Its core mission is to facilitate the discovery, safeguard the intellectual property, and enable the commercialization of scientific research, innovations, and established brands. The company's portfolio includes the extensive Web of Science suite, a collection of essential tools such as Web of Science, InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons, and Kopernio. These are designed to support organizations throughout the entire research lifecycle, from initial planning and funding to execution and utilization. Within the Life Sciences domain, Clarivate provides specialized products like Cortellis and Newport Integrity. These platforms cater to pharmaceutical and biotechnology companies, empowering their research endeavors, supplying vital market intelligence, and facilitating competitive monitoring during the development and launch phases of novel drugs. Its Derwent product line, comprising Derwent Innovation, Techstreet, and IP Professional Services, is dedicated to intellectual property management. These tools enable customers to evaluate the originality of potential products, establish their freedom to operate within design parameters, secure patent protection, analyze the competitive technological landscape, and ensure adherence to essential industry standards. Complementing these, CompuMark delivers trademark screening, search, and monitoring solutions vital for businesses and legal firms. Meanwhile, MarkMonitor empowers enterprises to establish, manage, optimize, and fortify their digital presence. Clarivate's diverse clientele spans government agencies, academic institutions, life science enterprises, and research and development corporations worldwide, with operations across the Americas, Middle East, Africa, Europe, and Asia Pacific regions. The company, initially known as Clarivate Analytics Plc, rebranded to Clarivate Plc in May 2020. It maintains its headquarters in London, United Kingdom.

Sector
Industrials
Industry
Professional Services
Exchange
UN
CEO
Matitiahu Shem Tov
Headquarters
London, Y9, GB
IPO Date
Oct 29, 2018
Employees
12,000
Website
www.clarivate.com

Key Metrics

Price
$1.47
Market Cap
$937.11M
Revenue (TTM)
$585.50M
Net Income (TTM)
$-40200000.00
EPS (TTM)

Clarivate Plc — Company Profile

Clarivate Plc operates as a prominent information services and analytics firm, furnishing structured data and insights. Its core mission is to facilitate the discovery, safeguard the intellectual property, and enable the commercialization of scientific research, innovations, and established brands. The company's portfolio includes the extensive Web of Science suite, a collection of essential tools such as Web of Science, InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons, and Kopernio. These are designed to support organizations throughout the entire research lifecycle, from initial planning and funding to execution and utilization. Within the Life Sciences domain, Clarivate provides specialized products like Cortellis and Newport Integrity. These platforms cater to pharmaceutical and biotechnology companies, empowering their research endeavors, supplying vital market intelligence, and facilitating competitive monitoring during the development and launch phases of novel drugs. Its Derwent product line, comprising Derwent Innovation, Techstreet, and IP Professional Services, is dedicated to intellectual property management. These tools enable customers to evaluate the originality of potential products, establish their freedom to operate within design parameters, secure patent protection, analyze the competitive technological landscape, and ensure adherence to essential industry standards. Complementing these, CompuMark delivers trademark screening, search, and monitoring solutions vital for businesses and legal firms. Meanwhile, MarkMonitor empowers enterprises to establish, manage, optimize, and fortify their digital presence. Clarivate's diverse clientele spans government agencies, academic institutions, life science enterprises, and research and development corporations worldwide, with operations across the Americas, Middle East, Africa, Europe, and Asia Pacific regions. The company, initially known as Clarivate Analytics Plc, rebranded to Clarivate Plc in May 2020. It maintains its headquarters in London, United Kingdom.

Sector
Industrials
Industry
Professional Services
Exchange
UN
CEO
Matitiahu Shem Tov
Headquarters
London, Y9, GB
IPO Date
Oct 29, 2018
Employees
12,000
Website
www.clarivate.com

Key Metrics

Price
$1.47
Market Cap
$937.11M
Revenue (TTM)
$585.50M
Net Income (TTM)
$-40200000.00
EPS (TTM)
-0.06
P/E (TTM)
-6.82
P/B (TTM)
0.20
Dividend Yield
0.00%
ROE (TTM)
-0.84%
ROA (TTM)
-0.37%
Operating Margin
5.16%
Beta
1.03

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Clarivate Plc operates as a prominent information services and analytics firm, furnishing structured data and insights. Its core mission is to facilitate the discovery, safeguard the intellectual property, and enable the commercialization of scientific research, innovations, and established brands. The company's portfolio includes the extensive Web of Science suite, a collection of essential tools such as Web of Science, InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons, and Kopernio. These are designed to support organizations throughout the entire research lifecycle, from initial planning and funding to execution and utilization. Within the Life Sciences domain, Clarivate provides specialized products like Cortellis and Newport Integrity. These platforms cater to pharmaceutical and biotechnology companies, empowering their research endeavors, supplying vital market intelligence, and facilitating competitive monitoring during the development and launch phases of novel drugs. Its Derwent product line, comprising Derwent Innovation, Techstreet, and IP Professional Services, is dedicated to intellectual property management. These tools enable customers to evaluate the originality of potential products, establish their freedom to operate within design parameters, secure patent protection, analyze the competitive technological landscape, and ensure adherence to essential industry standards. Complementing these, CompuMark delivers trademark screening, search, and monitoring solutions vital for businesses and legal firms. Meanwhile, MarkMonitor empowers enterprises to establish, manage, optimize, and fortify their digital presence. Clarivate's diverse clientele spans government agencies, academic institutions, life science enterprises, and research and development corporations worldwide, with operations across the Americas, Middle East, Africa, Europe, and Asia Pacific regions. The company, initially known as Clarivate Analytics Plc, rebranded to Clarivate Plc in May 2020. It maintains its headquarters in London, United Kingdom.

Website
www.clarivate.com
Location
London, Y9, GB
Phone44 20 7433 4000
Employees12,000
CEOMatitiahu Shem Tov
Sector
Industrials
Industry
Professional Services
IPO DateOct 29, 2018

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(680)

Expand
  • 144Collins Jonathan Mark3 Nov
  • 10-QQ3ended 30 Sept 20263 Nov
  • 8-KResults of Operations and Financial Condition3 Nov
  • 8-K/ACompletion of Acquisition or Disposition of Assets13 Oct
  • 4Statement of changes in beneficial ownership8 Oct
  • 8-KCompletion of Acquisition or Disposition of Assets6 Oct
  • 4Statement of changes in beneficial ownership2 Oct
  • 4Statement of changes in beneficial ownership2 Oct
  • 4Statement of changes in beneficial ownership2 Oct
  • 8-KOther Events24 Sep
  • 8-KOther Events23 Sep
  • 8-KOther Events17 Sep
  • 4Statement of changes in beneficial ownership18 Aug
  • 4Statement of changes in beneficial ownership18 Aug
  • 4Statement of changes in beneficial ownership17 Aug
  • 3Initial statement of beneficial ownership14 Aug
  • 4Statement of changes in beneficial ownership10 Aug
  • 4Statement of changes in beneficial ownership5 Aug
  • 144Snyder Andrew Miles3 Aug
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers29 Jul

News

  • What Clarivate (CLVT) Said on Its Q3 Earnings Call12:15AM
  • Clarivate Plc (CLVT) Q3 2026 Earnings Call Transcript3 Nov
  • Clarivate PLC (CLVT) Beats Q3 Earnings Estimates3 Nov
  • Clarivate Reports Third Quarter 2026 Results, Delivering Clear Path to Value Creation3 Nov
  • Clarivate to Bring Trusted Trademark Data into Microsoft Copilot Through IPOne2 Nov
  • Clarivate Demonstrates Global Demand For AI-native Web Of Science Research Intelligence22 Oct
  • Clarivate Demonstrates Global Demand For AI-native Web Of Science Research Intelligence22 Oct
  • Clarivate PLC (NYSE:CLVT) Stock Has Consensus Price Target of $3.02 According to Analysts16 Oct
  • Sterne Kessler and Clarivate Announce Partnership to Develop AI-enhanced Patent Workflow Solutions15 Oct
  • Clarivate Completes Sale of Life Sciences & Healthcare Segment, Advances Strategic Transformation6 Oct
  • Clarivate (NYSE:CLVT) Hits New 12-Month Low – What’s Next?5 Oct
  • Clarivate Announces Final Results of Offer to Purchase for Cash Certain of its Outstanding Debt Securities24 Sep
  • Clarivate Announces Pricing Terms of Offer to Purchase for Cash Certain of its Outstanding Debt Securities23 Sep
  • Clarivate to Report Third Quarter 2026 Results on November 3, 202622 Sep
  • Clarivate PLC (NYSE:CLVT) Receives $3.02 Consensus Price Target from Brokerages21 Sep
  • Clarivate Commences Offer to Purchase for Cash Certain of its Outstanding Debt Securities17 Sep
  • Clarivate Reveals Citation Laureates 2026 Recognizing Transformative Scientific Breakthroughs17 Sep
  • Clarivate Reveals Citation Laureates 2026 Recognizing Transformative Scientific Breakthroughs17 Sep
  • Accuserve Solutions Appoints Maroun S. Mourad as an Independent Board Member1 Sep
  • Clarivate Director Cornick Buys 900,000 Shares for $1.7 Million. What Does This Tell Investors About the Outlook for 2026?18 Aug

Mentions in Filings

  • … Use It as the Dominant Agent for PCN #2 ~90% 87%#1 Greater infection control1 Oral route of administration1,2 Report intent to prescribe mavorixafor3 Rated mavorixafor favorably (>5/7)3 Differentiator Differentiator 1. <strong>Clarivate</strong> qualitative market research 2026 n=20 60-minute interviews (n=3 PCP; n=6 community hematologist; n=11 academic hematologist/oncologist). 2. US hematology survey, 2024 (n=95). 3. X4 quantitative survey, 2025 (n=100). --- …
    X4 Pharmaceuticals, IncClarivate Plc·EX-99.1 - 8-K - Other Events·Q4 26·29 Oct
  • … children with primary immune thrombocytopenia (ITP). *Br J Haematol*. 2010 Oct;151(2):189-91. 7 Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. *Blood*. 2017 May 25;129(21):2829-2835. 8 <strong>Clarivate</strong> Landscape & Forecast for Immune Thrombocytopenic Purpura, 2018. 9 Provan D, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. *Blood Adv*. 2019;3(22):3 …
    HUTCHMED (China) LtdClarivate Plc·EX-99.1 - 6-K - Current report (foreign private issuer)·29 Oct·29 Oct
  • … kin fibrosis contributes to functional impairment, disability, and reduced quality of life \* Two therapies are approved for SSc-ILD; however, no treatment approved for SSc addresses multip le organ systems. Sources: 1. <strong>Clarivate</strong>/DRG (accessed 19-Aug-2024); 2. Public regulatory disclosures and prescribing information. Heart Kidney Liver Stomach approximately --- 26 Why SSc requires multi-pathway immune modulation BAFF- and IL-17–driven inflamma …
    Zura Bio LtdClarivate Plc·EX-99.2 - 8-K - Results of Operations and Financial Condition·Q4 26·27 Oct
  • … ell as the following private companies: Arcis Golf, The Orogen Group, and V Sports. Previously, Michael was the Chairman of the Board for the Federal Reserve Bank of Philadelphia, a member of the board of directors of <strong>Clarivate PLC</strong>, Duke Energy, Groupon Corporation (NASDAQ: GRPN), Hewlett Packard Enterprise (NYSE: HPE), and a trustee of Babson College. Michael is a graduate of the Owner/President Management Program at the Harvard Business School …
    Lucky Strike Entertainment CorpClarivate Plc·DEF 14A - Definitive proxy statement·Q2 27·23 Oct
  • … • Churchill Capital Corp, completed a $690 million initial public offering in September 2018 and merged in May 2019 with <strong>Clarivate</strong> Analytics. At closing of the business combination in May 2019, Churchill Capital Corp delivered approximately $705 million of gross transaction proceeds to Clarivate. There were redemptions of less than 0.01% by the public shareholders in connection with the business combination. Churchill Capital Corp arranged PIPE f …
    Churchill Capital Corp XIClarivate Plc·424B3 - PROSPECTUS·Q4 26·13 Oct
  • … Inc. and has served as a board member of several private companies, including serving as a board member of TCP Software and OverseeAI. Previously, Mr. Moran served as a board member for Duck Creek Technologies Inc. and <strong>Clarivate</strong> Analytics PLC. Mr. Moran received a B.S. from Boston College and an M.B.A. from Suffolk University. We believe that Mr. Moran is qualified to serve on our board of directors due to his extensive background in the techno …
    Intapp, Inc.Clarivate Plc·DEF 14A - Definitive proxy statement·Q2 27·6 Oct

Key Stats

Trading

Px/Chg 1D$1.47 / -1.01%
Avg Volume6.68M
Beta1.03
Mkt Cap937.11M
FD Mkt Cap1.30B

Float

Shrs Out/Float639.66M / 334.75M
Short Float0.18%
Days to Cover5.67
Stock Repurchased$18.10M

Current Valuation

EV5.04B
EV/EBITDA5.73
EV/Sales2.06
P/B0.20
P/S0.38
FCF Yield8.42%
ROE-0.84%
ROA-0.37%
Current Ratio0.84

Estimates

P/E-6.82
Est P/E0.00
Est EPS0.14
Est PEG0.00

Valuation

Metric5Yr AvgNov '23May '24Apr '25Apr '26Oct '26
PRICE-BASED RATIOS
Price / Earnings99.24-1.15-5.12-3.91529.69-23.31
Price / Sales1.751.721.780.972.661.60
Price / Book Value0.490.670.780.480.340.20
Price / Free Cash Flow9.5414.929.306.974.6611.88
ENTERPRISE VALUE METRICS
Enterprise Value7,767.110,718.810,498.26,787.35,792.15,039.2
Enterprise Value / Sales5.734.033.992.659.398.61
Enterprise Value / EBITDA-187.97-3.56-999.8314.8625.1323.53
Enterprise Value / EBIT52.84-2.88-14.61-25.10139.91166.86

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue6.9%1,876.92,659.82,628.82,556.72,455.2
Gross Income6.7%1,250.81,705.81,722.41,687.51,621.6
EBITDA11.7%532.2-3,008.3-10.5456.6828.7
EBIT—-5.7-3,718.8-718.8-270.471.5
Net Income-7.1%-270.5-3,960.2-911.2-636.7-201.1
EPS (Diluted)-16.3%-0.61-6.24-1.47-0.96-0.30
BALANCE SHEET
Cash & ST Inv-13.5%587.6348.8370.7295.2329.2
Total Assets-13.9%20,183.013,944.912,706.811,490.211,069.4
Total Liabilities-6.8%8,257.17,132.46,714.56,351.26,226.5
Total Shareholder Equity-20.2%11,925.96,812.55,992.35,139.04,842.9
CASH FLOW
Net Operating Cash Flow18%323.8509.3744.2646.6628.5
Cap Ex22.1%-118.5-202.9-242.5-289.1-263.2
Free Cash Flow15.5%205.3306.4501.7357.5365.3

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)1.87
Basic Shares639.66
Market Cap1,196.2
Diluted Shares640.70
Fully Diluted Shares Outstanding640.70
Fully Diluted Market Cap1,198.1
+Consolidated Debt4,334.4
−In-the-Money Convertible Debt—
+Capital Leases51.3
+Operating Leases—
−Cash & Equivalents-232.3
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value5,298.3

Segment data

Revenue

by Products and services

  • Recurring Revenues50%
  • Subscription Revenues39%
  • Re-occurring Revenues11%

Revenue

by Geography

  • North America53%
  • Emea27%
  • Asia Pacific20%

Related companies

Microsoft Corporation

MSFT US

Palantir Technologies Inc.

PLTR US

Oracle Corp

ORCL US

CrowdStrike Holdings, Inc.

CRWD US

Sap Se

SAP US

Shopify Inc.

SHOP US

Salesforce, Inc.

CRM US

ServiceNow, Inc.

NOW US

Cloudflare, Inc.

NET US

Snowflake Inc.

SNOW US

Automatic Data Processing Inc

ADP US

Datadog, Inc.

DDOG US

-0.06
P/E (TTM)
-6.82
P/B (TTM)
0.20
Dividend Yield
0.00%
ROE (TTM)
-0.84%
ROA (TTM)
-0.37%
Operating Margin
5.16%
Beta
1.03

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Clarivate Plc operates as a prominent information services and analytics firm, furnishing structured data and insights. Its core mission is to facilitate the discovery, safeguard the intellectual property, and enable the commercialization of scientific research, innovations, and established brands. The company's portfolio includes the extensive Web of Science suite, a collection of essential tools such as Web of Science, InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons, and Kopernio. These are designed to support organizations throughout the entire research lifecycle, from initial planning and funding to execution and utilization. Within the Life Sciences domain, Clarivate provides specialized products like Cortellis and Newport Integrity. These platforms cater to pharmaceutical and biotechnology companies, empowering their research endeavors, supplying vital market intelligence, and facilitating competitive monitoring during the development and launch phases of novel drugs. Its Derwent product line, comprising Derwent Innovation, Techstreet, and IP Professional Services, is dedicated to intellectual property management. These tools enable customers to evaluate the originality of potential products, establish their freedom to operate within design parameters, secure patent protection, analyze the competitive technological landscape, and ensure adherence to essential industry standards. Complementing these, CompuMark delivers trademark screening, search, and monitoring solutions vital for businesses and legal firms. Meanwhile, MarkMonitor empowers enterprises to establish, manage, optimize, and fortify their digital presence. Clarivate's diverse clientele spans government agencies, academic institutions, life science enterprises, and research and development corporations worldwide, with operations across the Americas, Middle East, Africa, Europe, and Asia Pacific regions. The company, initially known as Clarivate Analytics Plc, rebranded to Clarivate Plc in May 2020. It maintains its headquarters in London, United Kingdom.

Website
www.clarivate.com
Location
London, Y9, GB
Phone44 20 7433 4000
Employees12,000
CEOMatitiahu Shem Tov
Sector
Industrials
Industry
Professional Services
IPO DateOct 29, 2018

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(680)

Expand
  • 144Collins Jonathan Mark3 Nov
  • 10-QQ3ended 30 Sept 20263 Nov
  • 8-KResults of Operations and Financial Condition3 Nov
  • 8-K/ACompletion of Acquisition or Disposition of Assets13 Oct
  • 4Statement of changes in beneficial ownership8 Oct
  • 8-KCompletion of Acquisition or Disposition of Assets6 Oct
  • 4Statement of changes in beneficial ownership2 Oct
  • 4Statement of changes in beneficial ownership2 Oct
  • 4Statement of changes in beneficial ownership2 Oct
  • 8-KOther Events24 Sep
  • 8-KOther Events23 Sep
  • 8-KOther Events17 Sep
  • 4Statement of changes in beneficial ownership18 Aug
  • 4Statement of changes in beneficial ownership18 Aug
  • 4Statement of changes in beneficial ownership17 Aug
  • 3Initial statement of beneficial ownership14 Aug
  • 4Statement of changes in beneficial ownership10 Aug
  • 4Statement of changes in beneficial ownership5 Aug
  • 144Snyder Andrew Miles3 Aug
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers29 Jul

News

  • What Clarivate (CLVT) Said on Its Q3 Earnings Call12:15AM
  • Clarivate Plc (CLVT) Q3 2026 Earnings Call Transcript3 Nov
  • Clarivate PLC (CLVT) Beats Q3 Earnings Estimates3 Nov
  • Clarivate Reports Third Quarter 2026 Results, Delivering Clear Path to Value Creation3 Nov
  • Clarivate to Bring Trusted Trademark Data into Microsoft Copilot Through IPOne2 Nov
  • Clarivate Demonstrates Global Demand For AI-native Web Of Science Research Intelligence22 Oct
  • Clarivate Demonstrates Global Demand For AI-native Web Of Science Research Intelligence22 Oct
  • Clarivate PLC (NYSE:CLVT) Stock Has Consensus Price Target of $3.02 According to Analysts16 Oct
  • Sterne Kessler and Clarivate Announce Partnership to Develop AI-enhanced Patent Workflow Solutions15 Oct
  • Clarivate Completes Sale of Life Sciences & Healthcare Segment, Advances Strategic Transformation6 Oct
  • Clarivate (NYSE:CLVT) Hits New 12-Month Low – What’s Next?5 Oct
  • Clarivate Announces Final Results of Offer to Purchase for Cash Certain of its Outstanding Debt Securities24 Sep
  • Clarivate Announces Pricing Terms of Offer to Purchase for Cash Certain of its Outstanding Debt Securities23 Sep
  • Clarivate to Report Third Quarter 2026 Results on November 3, 202622 Sep
  • Clarivate PLC (NYSE:CLVT) Receives $3.02 Consensus Price Target from Brokerages21 Sep
  • Clarivate Commences Offer to Purchase for Cash Certain of its Outstanding Debt Securities17 Sep
  • Clarivate Reveals Citation Laureates 2026 Recognizing Transformative Scientific Breakthroughs17 Sep
  • Clarivate Reveals Citation Laureates 2026 Recognizing Transformative Scientific Breakthroughs17 Sep
  • Accuserve Solutions Appoints Maroun S. Mourad as an Independent Board Member1 Sep
  • Clarivate Director Cornick Buys 900,000 Shares for $1.7 Million. What Does This Tell Investors About the Outlook for 2026?18 Aug

Mentions in Filings

  • … Use It as the Dominant Agent for PCN #2 ~90% 87%#1 Greater infection control1 Oral route of administration1,2 Report intent to prescribe mavorixafor3 Rated mavorixafor favorably (>5/7)3 Differentiator Differentiator 1. <strong>Clarivate</strong> qualitative market research 2026 n=20 60-minute interviews (n=3 PCP; n=6 community hematologist; n=11 academic hematologist/oncologist). 2. US hematology survey, 2024 (n=95). 3. X4 quantitative survey, 2025 (n=100). --- …
    X4 Pharmaceuticals, IncClarivate Plc·EX-99.1 - 8-K - Other Events·Q4 26·29 Oct
  • … children with primary immune thrombocytopenia (ITP). *Br J Haematol*. 2010 Oct;151(2):189-91. 7 Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. *Blood*. 2017 May 25;129(21):2829-2835. 8 <strong>Clarivate</strong> Landscape & Forecast for Immune Thrombocytopenic Purpura, 2018. 9 Provan D, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. *Blood Adv*. 2019;3(22):3 …
    HUTCHMED (China) LtdClarivate Plc·EX-99.1 - 6-K - Current report (foreign private issuer)·29 Oct·29 Oct
  • … kin fibrosis contributes to functional impairment, disability, and reduced quality of life \* Two therapies are approved for SSc-ILD; however, no treatment approved for SSc addresses multip le organ systems. Sources: 1. <strong>Clarivate</strong>/DRG (accessed 19-Aug-2024); 2. Public regulatory disclosures and prescribing information. Heart Kidney Liver Stomach approximately --- 26 Why SSc requires multi-pathway immune modulation BAFF- and IL-17–driven inflamma …
    Zura Bio LtdClarivate Plc·EX-99.2 - 8-K - Results of Operations and Financial Condition·Q4 26·27 Oct
  • … ell as the following private companies: Arcis Golf, The Orogen Group, and V Sports. Previously, Michael was the Chairman of the Board for the Federal Reserve Bank of Philadelphia, a member of the board of directors of <strong>Clarivate PLC</strong>, Duke Energy, Groupon Corporation (NASDAQ: GRPN), Hewlett Packard Enterprise (NYSE: HPE), and a trustee of Babson College. Michael is a graduate of the Owner/President Management Program at the Harvard Business School …
    Lucky Strike Entertainment CorpClarivate Plc·DEF 14A - Definitive proxy statement·Q2 27·23 Oct
  • … • Churchill Capital Corp, completed a $690 million initial public offering in September 2018 and merged in May 2019 with <strong>Clarivate</strong> Analytics. At closing of the business combination in May 2019, Churchill Capital Corp delivered approximately $705 million of gross transaction proceeds to Clarivate. There were redemptions of less than 0.01% by the public shareholders in connection with the business combination. Churchill Capital Corp arranged PIPE f …
    Churchill Capital Corp XIClarivate Plc·424B3 - PROSPECTUS·Q4 26·13 Oct
  • … Inc. and has served as a board member of several private companies, including serving as a board member of TCP Software and OverseeAI. Previously, Mr. Moran served as a board member for Duck Creek Technologies Inc. and <strong>Clarivate</strong> Analytics PLC. Mr. Moran received a B.S. from Boston College and an M.B.A. from Suffolk University. We believe that Mr. Moran is qualified to serve on our board of directors due to his extensive background in the techno …
    Intapp, Inc.Clarivate Plc·DEF 14A - Definitive proxy statement·Q2 27·6 Oct

Key Stats

Trading

Px/Chg 1D$1.47 / -1.01%
Avg Volume6.68M
Beta1.03
Mkt Cap937.11M
FD Mkt Cap1.30B

Float

Shrs Out/Float639.66M / 334.75M
Short Float0.18%
Days to Cover5.67
Stock Repurchased$18.10M

Current Valuation

EV5.04B
EV/EBITDA5.73
EV/Sales2.06
P/B0.20
P/S0.38
FCF Yield8.42%
ROE-0.84%
ROA-0.37%
Current Ratio0.84

Estimates

P/E-6.82
Est P/E0.00
Est EPS0.14
Est PEG0.00

Valuation

Metric5Yr AvgNov '23May '24Apr '25Apr '26Oct '26
PRICE-BASED RATIOS
Price / Earnings99.24-1.15-5.12-3.91529.69-23.31
Price / Sales1.751.721.780.972.661.60
Price / Book Value0.490.670.780.480.340.20
Price / Free Cash Flow9.5414.929.306.974.6611.88
ENTERPRISE VALUE METRICS
Enterprise Value7,767.110,718.810,498.26,787.35,792.15,039.2
Enterprise Value / Sales5.734.033.992.659.398.61
Enterprise Value / EBITDA-187.97-3.56-999.8314.8625.1323.53
Enterprise Value / EBIT52.84-2.88-14.61-25.10139.91166.86

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue6.9%1,876.92,659.82,628.82,556.72,455.2
Gross Income6.7%1,250.81,705.81,722.41,687.51,621.6
EBITDA11.7%532.2-3,008.3-10.5456.6828.7
EBIT—-5.7-3,718.8-718.8-270.471.5
Net Income-7.1%-270.5-3,960.2-911.2-636.7-201.1
EPS (Diluted)-16.3%-0.61-6.24-1.47-0.96-0.30
BALANCE SHEET
Cash & ST Inv-13.5%587.6348.8370.7295.2329.2
Total Assets-13.9%20,183.013,944.912,706.811,490.211,069.4
Total Liabilities-6.8%8,257.17,132.46,714.56,351.26,226.5
Total Shareholder Equity-20.2%11,925.96,812.55,992.35,139.04,842.9
CASH FLOW
Net Operating Cash Flow18%323.8509.3744.2646.6628.5
Cap Ex22.1%-118.5-202.9-242.5-289.1-263.2
Free Cash Flow15.5%205.3306.4501.7357.5365.3

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)1.87
Basic Shares639.66
Market Cap1,196.2
Diluted Shares640.70
Fully Diluted Shares Outstanding640.70
Fully Diluted Market Cap1,198.1
+Consolidated Debt4,334.4
−In-the-Money Convertible Debt—
+Capital Leases51.3
+Operating Leases—
−Cash & Equivalents-232.3
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value5,298.3

Segment data

Revenue

by Products and services

  • Recurring Revenues50%
  • Subscription Revenues39%
  • Re-occurring Revenues11%

Revenue

by Geography

  • North America53%
  • Emea27%
  • Asia Pacific20%

Related companies

Microsoft Corporation

MSFT US

Palantir Technologies Inc.

PLTR US

Oracle Corp

ORCL US

CrowdStrike Holdings, Inc.

CRWD US

Sap Se

SAP US

Shopify Inc.

SHOP US

Salesforce, Inc.

CRM US

ServiceNow, Inc.

NOW US

Cloudflare, Inc.

NET US

Snowflake Inc.

SNOW US

Automatic Data Processing Inc

ADP US

Datadog, Inc.

DDOG US